All In MedTech

FDA Clearance Tracker · P160016

VERSANT HCV GENOTYPE 2.0 ASSAY (LiPA)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 14, 2017 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P160016
Device name
VERSANT HCV GENOTYPE 2.0 ASSAY (LiPA)
Applicant location
Gent
Received
Jun 6, 2016
Decided
Mar 14, 2017
Decision
Approved (reclassified)
Supplements
5 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3170

Every decision under product code OBF

FDA's approval statement

As written in FDA's record.

Approval for the VERSANT HCV Genotype 2.0 Assay (LiPA) is a line probe assay, which identifies Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes 1a and 1b in human serum or plasma (K2EDTA, ACD-A CPD, and CPDA) samples. The VERSANT HCV Genotype 2.0 Assay (LiPA) is intended to be used as an aid in the management of patients with chronic HCV infection to guide the selection of antiviral treatment.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OBF. The earliest in FDA's data is P120012, decided Jun 20, 2013.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Fujirebio Europe N.V.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.